• Bernstein sets a price target of $335 for Amgen Inc. (NASDAQ:AMGN), indicating a potential increase of about 1.38%.
• Amgen's current stock price is $330.06, with a year's high of $346.38 and a low of $261.43, showcasing its market volatility.
• The company faces a lawsuit from Sagebrush Health Services, potentially impacting its financial performance and reputation.

Amgen Inc. (NASDAQ:AMGN) is a leading pharmaceutical company known for its innovative therapies and treatments. On January 20, 2026, Bernstein set a price target of $335 for Amgen, while the stock was trading at $330.44. This suggests a potential increase of about 1.38% from the target price, indicating a positive outlook from Bernstein.

Currently, Amgen's stock price is $330.06, showing a slight decrease of $0.35 or -0.11%. The stock has fluctuated today, with a low of $321.71 and a high of $330.83. Over the past year, Amgen's stock has seen a high of $346.38 and a low of $261.43, reflecting its volatility in the market.

Amgen's market capitalization is approximately $177.73 billion, highlighting its significant presence in the pharmaceutical industry. The trading volume for the day is 971,158 shares on the NASDAQ exchange, indicating active investor interest in the stock.

However, Amgen faces legal challenges as Sagebrush Health Services, a nonprofit in Las Vegas, has filed a lawsuit against the company. The lawsuit alleges that Amgen unlawfully terminated discounted drug sales to Sagebrush's clinics and retracted millions in past discounts, affecting over 10,000 patients in Nevada.

This legal issue could impact Amgen's reputation and financial performance. Investors should monitor the situation closely, as it may influence the stock's future performance and the company's ability to meet Bernstein's price target of $335.